Table 3. Inflammatory factors detection for COVID-19 patients.
| Non-severe | Severe | |||||
| Age | <50 | 50~60 | 60~70 | ≥70 | Overall | (N=26) |
| N | (N=159) | (N=58) | (N=65) | (N=23) | (N=305) | (N=26) |
| CRP (mg/L) | ||||||
| high | 65(40.9%) | 40(69.0%) | 36(55.4%) | 15(65.2%) | 156(51.1%) | 26(100%) |
| N.A | 3(1.9%) | 1(1.7%) | 1(1.5%) | 0(0%) | 5(1.6%) | 0(0%) |
| normal | 91(57.2%) | 17(29.3%) | 28(43.1%) | 8(34.8%) | 144(47.2%) | 0 (0%) |
| hs-CRP (mg/L) | ||||||
| high | 76(47.8%) | 39(67.2%) | 42(64.6%) | 18(78.3%) | 175(57.4%) | 24(92.3%) |
| N.A | 3(1.9%) | 2(3.4%) | 1(1.5%) | 1(4.3%) | 7(2.3%) | 2(7.7%) |
| normal | 80(50.3%) | 17(29.3%) | 22(33.8%) | 4(17.4%) | 123(40.3%) | 0(0%) |
| IL-1β (pg/ml) | ||||||
| high | 23(14.5%) | 7(12.1%) | 7(10.8%) | 1(4.3%) | 38(12.5%) | 8(30.8%) |
| N | 99(62.3%) | 31(53.4%) | 36(55.4%) | 12(52.2%) | 178(58.4%) | 1(3.8%) |
| normal | 37(23.3%) | 20(34.5%) | 22(33.8%) | 10(43.5%) | 89(29.2%) | 17(65.4%) |
| IL-2 (pg/ml) | ||||||
| high | 1(0.6%) | 0(0%) | 0(0%) | 0(0%) | 1(0.3%) | 3(11.5%) |
| N | 61(38.4%) | 15(25.9%) | 17(26.2%) | 6(26.1%) | 99(32.5%) | 1(3.8%) |
| normal | 97(61.0%) | 43(74.1%) | 48(73.8%) | 17(73.9%) | 205(67.2%) | 22(84.6%) |
| IL-4 (pg/ml) | ||||||
| N | 61(38.4%) | 15(25.9%) | 17(26.2%) | 6(26.1%) | 99(32.5%) | 1(3.8%) |
| normal | 98(61.6%) | 43(74.1%) | 48(73.8%) | 17(73.9%) | 206(67.5%) | 25(96.2%) |
| IL-5 (pg/ml) | ||||||
| N | 99(62.3%) | 31(53.4%) | 36(55.4%) | 12(52.2%) | 178(58.4%) | 1(3.8%) |
| normal | 60(37.7%) | 27(46.6%) | 29(44.6%) | 11(47.8%) | 127(41.6%) | 21(80.8%) |
| high | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 4(15.4%) |
| IL-6 (pg/ml) | ||||||
| high | 12(7.5%) | 12(20.7%) | 12(18.5%) | 4(17.4%) | 40(13.1%) | 16(61.5%) |
| N | 61(38.4%) | 15(25.9%) | 17(26.2%) | 6(26.1%) | 99(32.5%) | 1(3.8%) |
| normal | 86(54.1%) | 31(53.4%) | 36(55.4%) | 13(56.5%) | 166(54.4%) | 9(34.6%) |
| IL-8 (pg/ml) | ||||||
| high | 3(1.9%) | 0(0%) | 1(1.5%) | 0(0%) | 4(1.3%) | 9(34.6%) |
| N | 99(62.3%) | 31(53.4%) | 36(55.4%) | 12(52.2%) | 178(58.4%) | 1(3.8%) |
| normal | 57(35.8%) | 27(46.6%) | 28(43.1%) | 11(47.8%) | 123(40.3%) | 16(61.5%) |
| IL-10 (pg/ml) | ||||||
| N | 61(38.4%) | 15(25.9%) | 17(26.2%) | 6(26.1%) | 99(32.5%) | 3(11.5%) |
| normal | 98(61.6%) | 43(74.1%) | 46(70.8%) | 17(73.9%) | 204(66.9%) | 1(3.8%) |
| high | 0(0%) | 0(0%) | 2(3.1%) | 0(0%) | 2(0.7%) | 22(84.6%) |
| IL-12P70 (pg/ml) | ||||||
| high | 2(1.3%) | 1(1.7%) | 0(0%) | 0(0%) | 3(1.0%) | 1(3.8%) |
| N | 99(62.3%) | 31(53.4%) | 36(55.4%) | 12(52.2%) | 178(58.4%) | 1(3.8%) |
| normal | 58(36.5%) | 26(44.8%) | 29(44.6%) | 11(47.8%) | 124(40.7%) | 24(92.3%) |
| IL-17 (pg/ml) | ||||||
| N | 61(38.4%) | 15(25.9%) | 17(26.2%) | 6(26.1%) | 99(32.5%) | 1(3.8%) |
| normal | 98(61.6%) | 43(74.1%) | 48(73.8%) | 17(73.9%) | 206(67.5%) | 24(92.3%) |
| high | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 1(3.8%) |
| TNF-α (pg/ml) | ||||||
| high | 2(1.3%) | 0(0%) | 0(0%) | 0(0%) | 2(0.7%) | 0(0%) |
| N | 61(38.4%) | 15(25.9%) | 18(27.7%) | 6(26.1%) | 100(32.8%) | 1(3.8%) |
| normal | 96(60.4%) | 43(74.1%) | 47(72.3%) | 17(73.9%) | 203(66.6%) | 25(96.2%) |
| IFN-α (pg/ml) | ||||||
| N | 99(62.3%) | 31(53.4%) | 37(56.9%) | 12(52.2%) | 179(58.7%) | 3(11.5%) |
| normal | 60(37.7%) | 27(46.6%) | 28(43.1%) | 11(47.8%) | 126(41.3%) | 23(88.5%) |
| IFN-γ (pg/ml) | ||||||
| high | 1(0.6%) | 1(1.7%) | 1(1.5%) | 0(0%) | 3(1.0%) | 0(0%) |
| N | 62(39.0%) | 15(25.9%) | 18(27.7%) | 6(26.1%) | 101(33.1%) | 1(3.8%) |
| normal | 96(60.4%) | 42(72.4%) | 46(70.8%) | 17(73.9%) | 201(65.9%) | 25(96.2%) |
| Endotoxin (pg/ml) | ||||||
| high | 51(32.1%) | 15(25.9%) | 19(29.2%) | 9(39.1%) | 94(30.8%) | 3(11.5%) |
| N | 20(12.6%) | 8(13.8%) | 6(9.2%) | 5(21.8%) | 39(12.8%) | 6(23.1%) |
| normal | 88(55.3%) | 35(60.3%) | 40(61.5%) | 9(39.1%) | 172(56.4%) | 17(65.4%) |
CRP, C-reactive protein; hs-CRP, high-sensitivity C-reactive protein; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor α; IFN-α, interferon-α; IFN-γ, interferon-γ.